371 related articles for article (PubMed ID: 34503087)
1. Soluble Biomarkers with Prognostic and Predictive Value in Advanced Non-Small Cell Lung Cancer Treated with Immunotherapy.
Honrubia-Peris B; Garde-Noguera J; García-Sánchez J; Piera-Molons N; Llombart-Cussac A; Fernández-Murga ML
Cancers (Basel); 2021 Aug; 13(17):. PubMed ID: 34503087
[TBL] [Abstract][Full Text] [Related]
2. Plasma Biomarkers and Immune Checkpoint Inhibitors in Non-Small Cell Lung Cancer: New Tools for Better Patient Selection?
Costantini A; Takam Kamga P; Dumenil C; Chinet T; Emile JF; Giroux Leprieur E
Cancers (Basel); 2019 Aug; 11(9):. PubMed ID: 31470546
[TBL] [Abstract][Full Text] [Related]
3. PD-1/PD-L1 Blockade Therapy in Advanced Non-Small-Cell Lung Cancer: Current Status and Future Directions.
Xia L; Liu Y; Wang Y
Oncologist; 2019 Feb; 24(Suppl 1):S31-S41. PubMed ID: 30819829
[TBL] [Abstract][Full Text] [Related]
4. Association of Survival and Immune-Related Biomarkers With Immunotherapy in Patients With Non-Small Cell Lung Cancer: A Meta-analysis and Individual Patient-Level Analysis.
Yu Y; Zeng D; Ou Q; Liu S; Li A; Chen Y; Lin D; Gao Q; Zhou H; Liao W; Yao H
JAMA Netw Open; 2019 Jul; 2(7):e196879. PubMed ID: 31290993
[TBL] [Abstract][Full Text] [Related]
5. The clinical utility of tumor mutational burden in non-small cell lung cancer.
Greillier L; Tomasini P; Barlesi F
Transl Lung Cancer Res; 2018 Dec; 7(6):639-646. PubMed ID: 30505708
[TBL] [Abstract][Full Text] [Related]
6. Tumor mutational burden assessed by targeted NGS predicts clinical benefit from immune checkpoint inhibitors in non-small cell lung cancer.
Alborelli I; Leonards K; Rothschild SI; Leuenberger LP; Savic Prince S; Mertz KD; Poechtrager S; Buess M; Zippelius A; Läubli H; Haegele J; Tolnay M; Bubendorf L; Quagliata L; Jermann P
J Pathol; 2020 Jan; 250(1):19-29. PubMed ID: 31471895
[TBL] [Abstract][Full Text] [Related]
7. Immune Checkpoint Inhibitors (ICIs) in Non-Small Cell Lung Cancer (NSCLC).
Yoneda K; Imanishi N; Ichiki Y; Tanaka F
J UOEH; 2018; 40(2):173-189. PubMed ID: 29925736
[TBL] [Abstract][Full Text] [Related]
8. Efficacy of Immune Checkpoint Inhibitors in KRAS-Mutant Non-Small Cell Lung Cancer (NSCLC).
Jeanson A; Tomasini P; Souquet-Bressand M; Brandone N; Boucekine M; Grangeon M; Chaleat S; Khobta N; Milia J; Mhanna L; Greillier L; Biemar J; Nanni I; Ouafik L; Garcia S; Mazières J; Barlesi F; Mascaux C
J Thorac Oncol; 2019 Jun; 14(6):1095-1101. PubMed ID: 30738221
[TBL] [Abstract][Full Text] [Related]
9. Recognizing Prognostic and Predictive Biomarkers in the Treatment of Non-Small Cell Lung Cancer (NSCLC) with Immune Checkpoint Inhibitors (ICIs).
Giustini N; Bazhenova L
Lung Cancer (Auckl); 2021; 12():21-34. PubMed ID: 33790679
[TBL] [Abstract][Full Text] [Related]
10. Predictive Biomarkers of Response to Immunotherapy in Metastatic Renal Cell Cancer.
Raimondi A; Sepe P; Zattarin E; Mennitto A; Stellato M; Claps M; Guadalupi V; Verzoni E; de Braud F; Procopio G
Front Oncol; 2020; 10():1644. PubMed ID: 32903369
[TBL] [Abstract][Full Text] [Related]
11. Predictive biomarkers for response to immune checkpoint inhibitors in lung cancer: PD-L1 and beyond.
Uruga H; Mino-Kenudson M
Virchows Arch; 2021 Jan; 478(1):31-44. PubMed ID: 33486574
[TBL] [Abstract][Full Text] [Related]
12. Circulating Biomarkers of Response and Toxicity of Immunotherapy in Advanced Non-Small Cell Lung Cancer (NSCLC): A Comprehensive Review.
Indini A; Rijavec E; Grossi F
Cancers (Basel); 2021 Apr; 13(8):. PubMed ID: 33918661
[TBL] [Abstract][Full Text] [Related]
13. Circulating Tumor Cell PD-L1 Expression as Biomarker for Therapeutic Efficacy of Immune Checkpoint Inhibition in NSCLC.
Kloten V; Lampignano R; Krahn T; Schlange T
Cells; 2019 Aug; 8(8):. PubMed ID: 31374957
[TBL] [Abstract][Full Text] [Related]
14. Subunits of ARID1 serve as novel biomarkers for the sensitivity to immune checkpoint inhibitors and prognosis of advanced non-small cell lung cancer.
Sun D; Tian L; Zhu Y; Wo Y; Liu Q; Liu S; Li H; Hou H
Mol Med; 2020 Aug; 26(1):78. PubMed ID: 32791957
[TBL] [Abstract][Full Text] [Related]
15. Tumor mutational burden assessment as a predictive biomarker for immunotherapy in lung cancer patients: getting ready for prime-time or not?
Heeke S; Hofman P
Transl Lung Cancer Res; 2018 Dec; 7(6):631-638. PubMed ID: 30505707
[TBL] [Abstract][Full Text] [Related]
16. Clinical Implications of Circulating Tumor DNA Tumor Mutational Burden (ctDNA TMB) in Non-Small Cell Lung Cancer.
Chae YK; Davis AA; Agte S; Pan A; Simon NI; Iams WT; Cruz MR; Tamragouri K; Rhee K; Mohindra N; Villaflor V; Park W; Lopes G; Giles FJ
Oncologist; 2019 Jun; 24(6):820-828. PubMed ID: 30867242
[TBL] [Abstract][Full Text] [Related]
17. Clinical utility of tumor mutational burden in patients with non-small cell lung cancer treated with immunotherapy.
Hendriks LE; Rouleau E; Besse B
Transl Lung Cancer Res; 2018 Dec; 7(6):647-660. PubMed ID: 30505709
[TBL] [Abstract][Full Text] [Related]
18. Narrative review: blood and tumor biomarker testing in non-small cell lung cancer without an oncogenic driver.
Stinchcombe TE
Transl Lung Cancer Res; 2023 Jan; 12(1):158-167. PubMed ID: 36762068
[TBL] [Abstract][Full Text] [Related]
19. Comprehensive assessment of PD-L1 expression, tumor mutational burden and oncogenic driver alterations in non-small cell lung cancer patients treated with immune checkpoint inhibitors.
Yoh K; Matsumoto S; Furuya N; Nishino K; Miyamoto S; Oizumi S; Okamoto N; Itani H; Kuyama S; Nakamura A; Nishi K; Fukuda I; Tsuta K; Hayashi Y; Motoi N; Ishii G; Goto K
Lung Cancer; 2021 Sep; 159():128-134. PubMed ID: 34333203
[TBL] [Abstract][Full Text] [Related]
20. HLA-corrected tumor mutation burden and homologous recombination deficiency for the prediction of response to PD-(L)1 blockade in advanced non-small-cell lung cancer patients.
Shim JH; Kim HS; Cha H; Kim S; Kim TM; Anagnostou V; Choi YL; Jung HA; Sun JM; Ahn JS; Ahn MJ; Park K; Park WY; Lee SH
Ann Oncol; 2020 Jul; 31(7):902-911. PubMed ID: 32320754
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]